PMID- 24023843
OWN - NLM
STAT- MEDLINE
DCOM- 20140408
LR  - 20220318
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 9
DP  - 2013
TI  - Clinical importance of steps taken per day among persons with multiple sclerosis.
PG  - e73247
LID - 10.1371/journal.pone.0073247 [doi]
LID - e73247
AB  - BACKGROUND: The number of steps taken per day (steps/day) provides a reliable and 
      valid outcome of free-living walking behavior in persons with multiple sclerosis 
      (MS). OBJECTIVE: This study examined the clinical meaningfulness of steps/day 
      using the minimal clinically important difference (MCID) value across stages 
      representing the developing impact of MS. METHODS: This study was a secondary 
      analysis of de-identified data from 15 investigations totaling 786 persons with 
      MS and 157 healthy controls. All participants provided demographic information 
      and wore an accelerometer or pedometer during the waking hours of a 7-day period. 
      Those with MS further provided real-life, health, and clinical information and 
      completed the Multiple Sclerosis Walking Scale-12 (MSWS-12) and Patient 
      Determined Disease Steps (PDDS) scale. MCID estimates were based on regression 
      analyses and analysis of variance for between group differences. RESULTS: The 
      mean MCID from self-report scales that capture subtle changes in ambulation 
      (1-point change in PDSS scores and 10-point change in MSWS-12 scores) was 779 
      steps/day (14% of mean score for MS sample); the mean MCID for clinical/health 
      outcomes (MS type, duration, weight status) was 1,455 steps/day (26% of mean 
      score for MS sample); real-life anchors (unemployment, divorce, assistive device 
      use) resulted in a mean MCID of 2,580 steps/day (45% of mean score for MS 
      sample); and the MCID for the cumulative impact of MS (MS vs. control) was 2,747 
      steps/day (48% of mean score for MS sample). CONCLUSION: The change in motion 
      sensor output of ~800 steps/day appears to represent a lower-bound estimate of 
      clinically meaningful change in free-living walking behavior in interventions of 
      MS.
FAU - Motl, Robert W
AU  - Motl RW
AD  - Department of Kinesiology and Community Health, University of Illinois at 
      Urbana-Champaign, Urbana, Illinois, United States of America.
FAU - Pilutti, Lara A
AU  - Pilutti LA
FAU - Learmonth, Yvonne C
AU  - Learmonth YC
FAU - Goldman, Myla D
AU  - Goldman MD
FAU - Brown, Ted
AU  - Brown T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130904
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Analysis of Variance
MH  - Case-Control Studies
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/diagnosis/*physiopathology
MH  - Regression Analysis
MH  - Time Factors
MH  - *Walking
PMC - PMC3762863
COIS- Competing Interests: Acorda Therapeutics funded this study. RWM is a consultant 
      for Acorda Therapeutics and Biogen Idec. LAP and YCL report no conflicts of 
      interest. MDG has served as a consultant for Acorda Therapeutics and Novartis 
      Pharmaceuticals, but does not report any current conflicts of interest. TB is a 
      consultant for Acorda Therapeutics, Biogen Idec, Genzyme, Pfizer, and Teva. There 
      are no patents, products in development or marked products to declare. This does 
      not alter the authors' adherence to all the PLOS ONE policies on sharing data and 
      materials.
EDAT- 2013/09/12 06:00
MHDA- 2014/04/09 06:00
PMCR- 2013/09/04
CRDT- 2013/09/12 06:00
PHST- 2013/04/01 00:00 [received]
PHST- 2013/07/18 00:00 [accepted]
PHST- 2013/09/12 06:00 [entrez]
PHST- 2013/09/12 06:00 [pubmed]
PHST- 2014/04/09 06:00 [medline]
PHST- 2013/09/04 00:00 [pmc-release]
AID - PONE-D-13-13526 [pii]
AID - 10.1371/journal.pone.0073247 [doi]
PST - epublish
SO  - PLoS One. 2013 Sep 4;8(9):e73247. doi: 10.1371/journal.pone.0073247. eCollection 
      2013.